<DOC>
	<DOC>NCT03053180</DOC>
	<brief_summary>This prospective, multi-center, observational study is designed to assess the real world effectiveness and safety of paritaprevir/r - ombitasvir with dasabuvir (3DAA [direct-acting antiviral agent] ABBVIE REGIMEN) without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection and compensated liver cirrhosis in Russia.</brief_summary>
	<brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>ABBVIE REGIMEN will be prescribed by physicians according to the routine clinical practice Treatmentna√Øve or IFN/RBVexperienced participants with confirmed CHC Gt1b and compensated liver cirrhosis, receiving therapy with the interferonfree ABBVIE 3D REGIMEN initiated not earlier than 2 weeks before the enrollment or the initiation is planned not later than 2 weeks after the day of enrollment in accordance to standard of care and in line with the current local label Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial Coadministration ribavirin (RBV) with the ABBVIE REGIMEN Participants with Child Pugh B and C cirrhosis Participants with a history of prior directacting antiviral agent (DAA) therapy Any other contraindications to the administration of ABBVIE REGIMEN according to the label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Chronic Hepatitis C genotype 1b (GT1b)</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Compensated liver cirrhosis</keyword>
	<keyword>Ribavirin free</keyword>
	<keyword>Ritonavir</keyword>
</DOC>